Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
- Objective responses and promising anti-tumor activity observed in several patients across multiple cohorts in the ongoing Phase I/IIa clinical trial
- Data reinforces the therapeutic potential and safety profile of HDP-101 in relapsed or refractory multiple myeloma.
- R&D Webinar to be hosted on 11 November 2025 at 05:00 pm CET (08:00 am PST)
Ladenburg, Germany, 3 November 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announced the presentation of new clinical data from its ongoing Phase I/IIa clinical study evaluating its lead Amanitin-based ADC candidate, HDP-101 (INN: pamlectabart tismanitin), at the 16th Annual World ADC Congress, taking place in San Diego, California, from 3 to 6 November 2025.
HDP-101 (INN: pamlectabart tismanitin) is an anti-BCMA antibody-drug conjugate being investigated for the treatment of relapsed or refractory multiple myeloma, a bone marrow cancer with a high unmet medical need. Phase I of the ongoing study is a dose-escalation trial designed to determine the optimal and safe dose level of HDP-101 in preparation for subsequent Phase II clinical evaluation.
Professor Andreas Pahl, Chief Executive Officer of Heidelberg Pharma, will present an update from patient cohort 8 including efficacy data of the open-label, multicenter Phase I/IIa study evaluating HDP-101 in patients with relapsed or refractory multiple myeloma.
Details of the presentation at 16th Annual World ADC Congress:
Presentation title: From Bench to Breakthrough: The Evolution of Amanitin ADCs – Insights from HDP-101 Phase I/II & the Future of Payload Differentiation
|
Speaker: |
Professor Andreas Pahl, Chief Executive Officer |
|
Date and time: |
Wednesday, 5 November 2025, 5:00 pm (PST) |
|
Location: |
R&D Webinar to take place with Key Opinion Leader
Following the World ADC Congress, Heidelberg Pharma will host an R&D webinar on 11 November 2025 at 05:00 pm CET (11:00 am EST; 08:00 am PST), for investors, analysts, and media.
The R&D webinar will feature presentations by the Heidelberg Pharma management team, alongside Key Opinion Leader (KOL) Professor Marc-Steffen Raab, Head of the Myeloma Center at the University Hospital Heidelberg and clinical investigator of the study.
Webinar participants will have the opportunity to submit questions in advance of the webinar or ask questions live during the event.
For further information on the R&D webinar, or to register your attendance, please use the link below:
https://us06web.zoom.us/webinar/register/WN_AG_mESPaT-aSsm8_O2DllA
A recording of the R&D webinar will be accessible via the press & investor section of the Company website after the event.